CONECT-AML project is structured around 5 working groups (work-packages, or WP) whose aims are:

  • WP1 “AML Predisposition and genomics” : its objective is to better characterize the genetic abnormalities associated with pediatric AML; to uncover unknown genetic predispositions; to study the process of appearance of myeloid leukemia cells in three known predisposition contexts (congenital neutropenia, GATA2 gene mutations, Fanconi anemia).


  • WP2 “Modulation of the NK synapse/ LSC by the medullary microenvironment in pediatric AML “: its objective is to study the interactions between leukemic stem cells with their immediate environment, mesenchymal stem cells and innate killer lymphocytes (NK cells).


  • WP3 “Development of representative models of pediatric AML and therapeutic perspectives”: its objective is to develop new experimental models for the study of tumor cells: in vitro culture and PDX models (xenograft derived from the patient); these models enable to evaluate the sensitivity of leukemia cells to new anti-cancer agents.


  • WP4 “MET-LEA: Metabolic syndrome in patients cured of their pediatric AML”: Adults cured of AML during childhood may present metabolic problems (diabetes, overweight, cholesterol, hypertension) several years after healing. The project will evaluate, in cured patients, the efficacy of specific management of these metabolic side effects of AML treatment.


  • WP5 “IMPROVE” (Implementation, Management, Participatory Reflection, OVErview of the project). This WP aims to promote synergies and reflection between teams; identify the most promising results and accelerate transfer to patients; develop other collaborations and associated projects; explain the ethical aspects and issues of research; promote the training of clinical physicians in molecular medicine; inform the general public.